{
    "clinical_study": {
        "@rank": "90814", 
        "acronym": "TED", 
        "arm_group": {
            "arm_group_label": "Insulin glargine and Oral anti diabetic treatment(s)", 
            "arm_group_type": "Experimental", 
            "description": "Insulin glargine: Lantus\nAdd basal insulin: starting with 0.2 U/kg/day or 10 U/day\nAdjust insulin glargine dose according to Fasting blood glucose\nOral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
        }, 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To investigate the efficacy(HbA1c)  at 6 months after adding basal insulin therapy (insulin\n      glargine) to dipeptidyl peptidase-IV (DPP-IV)  and metformin plus or minus sulphonylurea\n\n      Secondary Objectives:\n\n        1. To assess the efficacy by adding insulin glargine\n\n        2. To assess insulin dose\n\n        3. Safety"
        }, 
        "brief_title": "Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "28 weeks (Screening: About 2 weeks/Treatment: 24 weeks (6 months)/Follow-up: 2 weeks)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Patients with type 2 Diabetes mellitus  \u2265 20 aged\n\n          -  Patients who are treated with DPP- 4 for at least 3 months before informed consent\n             with metformin plus or minus sulphonylurea inadequately controlled with HbA1c \u2265 7.5%\n\n          -  Be able and voluntarily agree to participate in this study by signing a written\n             informed consent\n\n        Exclusion criteria:\n\n          -  Diabetes patients other than Type 2 (eg. Type 1 Diabetes mellitus, pancreatic\n             disease, secondary diabetes)\n\n          -  HbA1c > 11% at screening\n\n          -  History of continuous basal insulin treatment within 1 year before screening\n\n          -  History of diabetic acidosis (including keto-acidosis) within 1 year before screening\n\n          -  History of myocardial infarct, stroke or heart failure related admission within 3\n             months before screening\n\n          -  History of drug or alcoholic abuse within 6 months before screening\n\n          -  Weight change \u2265 5 kg within 3 months before screening\n\n          -  History of hypoglycemic unawareness\n\n          -  Systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg regardless\n             of taking anti-hypertensive, or uncontrolled hypertension\n\n          -  Active malignant cancer, major systemic disease, clinically significant diabetic\n             retinopathy, macular edema necessitating laser treatment, abnormal clinical finding\n             from physical examination, lab analysis, electrocardiogram or vital sign, which can\n             be regarded as to prevent safe completion of clinical study or to make efficacy\n             assessment difficult by investigator or co-investigator at screening\n\n          -  Pregnant or lactating women\n\n          -  Women of child bearing potential (Pre-menopause or not surgically infertile within 3\n             months before screening) who match two conditions below:\n\n          -  Negative serum pregnancy test at screening\n\n          -  Using medically proven effective contraceptive method\n\n          -  Hypersensitivity to investigational drugs\n\n          -  Lab finding at screening:\n\n          -  Abnormal liver function: Alanine transaminase or Alkaline phosphatase > 3 times of\n             upper limit of normal range\n\n          -  Renal insufficiency: Men with serum Cr \u2265 1.5 mg/dL (\u2265 133\u00b5mol/L), women with serum Cr\n             \u2265 1.4 mg/dL (\u2265 124 \u00b5mol/L)\n\n          -  Use of anti-obese drug within 3 months before screening\n\n          -  Has been using drugs that can influence glucose metabolism (systemic corticosteroid,\n             thyroid hormone) within 3 months before screening or has possibility of using these\n             drug during the investigational period\n\n          -  Has participated in clinical studies of any investigational drugs within 3 months\n             before screening\n\n          -  Considered not physically or psychologically appropriate to participate in clinical\n             study by investigator\n\n          -  Not willing to comply with scheduled visit, self-inject insulin, or self-monitor\n             blood glucose level\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02027753", 
            "org_study_id": "LANTUL06638", 
            "secondary_id": "U1111-1149-1632"
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin glargine and Oral anti diabetic treatment(s)", 
                "description": "Pharmaceutical form: solution Route of administration: subcutaneous", 
                "intervention_name": "INSULIN GLARGINE", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine and Oral anti diabetic treatment(s)", 
                "description": "Pharmaceutical form: tablet   Route of administration: oral", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine and Oral anti diabetic treatment(s)", 
                "description": "Pharmaceutical form: tablet Route of administration: oral", 
                "intervention_name": "DPP-4 inhibitor", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine and Oral anti diabetic treatment(s)", 
                "description": "Pharmaceutical form: tablet Route of administration: oral", 
                "intervention_name": "Sulphonylurea", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Hypoglycemic Agents", 
                "Metformin", 
                "Insulin, Long-Acting", 
                "Dipeptidyl-Peptidase IV Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Sanofi-Aventis Administrative Office"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine)", 
        "overall_contact": {
            "email": "Contact-US@sanofi.com", 
            "last_name": "Trial Transparency Team"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rate (percentage of patients who meet the target HbA1c \u22647%) at  week 24 (6 months) after adding insulin therapy", 
            "safety_issue": "No", 
            "time_frame": "week 24 (6 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02027753"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with HbA1c \u22647%", 
                "safety_issue": "No", 
                "time_frame": "week 12 (3 months)"
            }, 
            {
                "measure": "Change from baseline in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "week 12 (3 months), week 24 (6 months)"
            }, 
            {
                "measure": "Percentage of patients with HbA1c \u22646.5%", 
                "safety_issue": "No", 
                "time_frame": "week 12 (3 months), week 24 (6 months)"
            }, 
            {
                "measure": "Change from baseline in Fasting Plasma glucose (FPG), 2hr-Postprandial Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "week 12 (3 months), week 24 (6 months)"
            }, 
            {
                "measure": "Total daily insulin dose", 
                "safety_issue": "No", 
                "time_frame": "week 24 (6 months)"
            }, 
            {
                "measure": "Fasting blood glucose (FBG) values", 
                "safety_issue": "No", 
                "time_frame": "During 3 consecutive days before baseline, week 12, Week 24"
            }, 
            {
                "measure": "7-point Self Monitoring of Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "During 2 days within 7 days before baseline, week 12, week 24"
            }, 
            {
                "measure": "Weight change from baseline", 
                "safety_issue": "No", 
                "time_frame": "week 24 (6 months)"
            }, 
            {
                "measure": "Number of Patients with Hypoglycemic Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "Number of Patients with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}